Bugat R - Search Results

1

Factors affecting pharmacokinetic variability of oral topotecan: a population analysis.

Léger F, Loos WJ, Fourcade J, Bugat R, Goffinet M, Mathijssen RH, Verweij J, Sparreboom A, Chatelut E. Léger F, et al. Among authors: bugat r. Br J Cancer. 2004 Jan 26;90(2):343-7. doi: 10.1038/sj.bjc.6601469. Br J Cancer. 2004. PMID: 14735174 Free PMC article. Clinical Trial.

2

Mechanism-based models for topotecan-induced neutropenia.

Léger F, Loos WJ, Bugat R, Mathijssen RH, Goffinet M, Verweij J, Sparreboom A, Chatelut E. Léger F, et al. Among authors: bugat r. Clin Pharmacol Ther. 2004 Dec;76(6):567-78. doi: 10.1016/j.clpt.2004.08.008. Clin Pharmacol Ther. 2004. PMID: 15592328

3

Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation.

Delord JP, Léger F, Canal P, Poublanc M, Bugat R, Chatelut E. Delord JP, et al. Among authors: bugat r. Cancer Chemother Pharmacol. 2006 Aug;58(2):189-94. doi: 10.1007/s00280-005-0142-0. Epub 2005 Nov 22. Cancer Chemother Pharmacol. 2006. PMID: 16328415 Clinical Trial.

4

Population pharmacokinetics of topotecan: intraindividual variability in total drug.

Montazeri A, Boucaud M, Lokiec F, Pinguet F, Culine S, Déporte-Féty R, Albin N, Laguerre B, Goupil A, Bugat R, Canal P, Chatelut E. Montazeri A, et al. Among authors: bugat r. Cancer Chemother Pharmacol. 2000;46(5):375-81. doi: 10.1007/s002800000161. Cancer Chemother Pharmacol. 2000. PMID: 11127941 Clinical Trial.

5

Individual adaptive dosing of topotecan in ovarian cancer.

Montazeri A, Culine S, Laguerre B, Pinguet F, Lokiec F, Albin N, Goupil A, Déporte-Féty R, Bugat R, Canal P, Chatelut E. Montazeri A, et al. Among authors: bugat r. Clin Cancer Res. 2002 Feb;8(2):394-9. Clin Cancer Res. 2002. PMID: 11839654 Clinical Trial.

6

Population pharmacokinetics of oxaliplatin.

Delord JP, Umlil A, Guimbaud R, Grégoire N, Lafont T, Canal P, Bugat R, Chatelut E. Delord JP, et al. Among authors: bugat r. Cancer Chemother Pharmacol. 2003 Feb;51(2):127-31. doi: 10.1007/s00280-002-0550-3. Epub 2002 Dec 4. Cancer Chemother Pharmacol. 2003. PMID: 12647013

7

[Relations between hematological toxicity and total and free plasma levels of etoposide in daily oral administration].

Lavit M, Chevreau C, Chatelut E, De Fenin V, Lochon I, Houin G, Bugat R, Canal P. Lavit M, et al. Among authors: bugat r. Bull Cancer. 1995 Aug;82(8):660-4. Bull Cancer. 1995. PMID: 7492822 French.

8

Prediction of carboplatin clearance from standard morphological and biological patient characteristics.

Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, Roché H, Houin G, Bugat R. Chatelut E, et al. Among authors: bugat r. J Natl Cancer Inst. 1995 Apr 19;87(8):573-80. doi: 10.1093/jnci/87.8.573. J Natl Cancer Inst. 1995. PMID: 7752255

9

A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer.

Chatelut E, Chevreau C, Brunner V, Martinez M, Houin G, Bugat R, Canal P. Chatelut E, et al. Among authors: bugat r. Cancer Chemother Pharmacol. 1995;35(5):391-6. doi: 10.1007/s002800050252. Cancer Chemother Pharmacol. 1995. PMID: 7850920 Clinical Trial.

10

[Prediction of carboplatin clearance from morphological and biological patient characteristics].

Chatelut E, Dezeuze A, Lavit M, Chevreau C, Pujol A, Boneu A, Roché H, Houin G, Bugat R, Canal P. Chatelut E, et al. Among authors: bugat r. Bull Cancer. 1995 Nov;82(11):946-53. Bull Cancer. 1995. PMID: 8535021 French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

184 results

Search Page